Portal de Periódicos da CAPES

Urinary Interleukin-8 Predicts the Response of Standard and Low Dose Intravesical Bacillus Calmette-Guerin (Modified Danish 1331 Strain) for Superficial Bladder Cancer

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 5 Linguagem: Inglês

10.1016/s0022-5347(05)64361-3

1527-3792

Anant Kumar, Deepak Dubey, Pradeep Bansal, Anil Mandhani, Sita Naik,

Urinary Bladder and Prostate Research

No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Nov 2002Urinary Interleukin-8 Predicts the Response of Standard and Low Dose Intravesical Bacillus Calmette-Guerin (Modified Danish 1331 Strain) for Superficial Bladder Cancer ANANT KUMAR, DEEPAK DUBEY, PRADEEP BANSAL, ANIL MANDHANI, and SITA NAIK ANANT KUMARANANT KUMAR , DEEPAK DUBEYDEEPAK DUBEY , PRADEEP BANSALPRADEEP BANSAL , ANIL MANDHANIANIL MANDHANI , and SITA NAIKSITA NAIK View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64361-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determined whether the proinflammatory cytokine interleukin-8 (IL-8) can serve as a predictor for the response to standard (120 mg.) and low (40 mg.) dose intravesical bacillus Calmette-Guerin (BCG) (modified Danish 1331 strain) for managing superficial bladder cancer in patients at risk for recurrence and progression. Materials and Methods: We randomized 26 patients with superficial bladder cancer to receive a 6-week course of standard dose 120 mg. or low dose 40 mg. intravesical BCG. Voided urine samples were collected immediately before and after (2 and 4 hours) BCG instillation. Urine samples were centrifuged at 1,500 rpm for 8 minutes and stored at −80C. IL-8 was measured using a commercial enzyme-linked immunosorbent assay. Patients were monitored for recurrence, progression and side effects of BCG treatment at 3-month intervals. Results: At a median followup of 24 months (range 12 to 30), 5 and 6 patients who received a standard and low dose, respectively had disease recurrence and/or progression (nonresponders). At 4 hours after BCG mean Il-8 levels plus or minus SD were significantly higher in responders than in nonresponders (1,099.33 ± 708.51 versus 261.82 ± 182.66 pg./ml., p = 0.001). There was no difference at 4 hours in mean IL-8 levels in the standard and low dose groups (596.92 ± 546 and 893 ± 798.67 pg./ml., respectively, p = 0.28). In all patients who remained disease-free IL-8 levels were greater than 400 pg./ml. In 9 of the 11 patients with disease recurrence/progression IL-8 levels were less than 400 pg./ml. Conclusions: IL-8 secretion after the initial intravesical BCG instillation strongly correlates with the possibility of future recurrence/progression. The quantitative IL-8 response to low and standard dose intravesical BCG (Danish 1331) is similar. References 1 : BCG intravesical instillations: recommendations for side-effects management. Eur Urol2000; 37: 33. Google Scholar 2 : Phase II trials in Ta, T1 cancer. The marker tumour concept. Br J Urol1996; 77: 634. Google Scholar 3 : Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol1996; 155: 477. Link, Google Scholar 4 : Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol1997; 158: 1340. Link, Google Scholar 5 : Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients. J Urol1997; 158: 1728. Link, Google Scholar 6 : Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol1998; 159: 1054. Link, Google Scholar 7 : Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol2000; 164: 2129. Link, Google Scholar 8 : Modified induction course: a solution to side-effects?. Eur Urol2000; 37: 31. Google Scholar 9 : Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol2000; 163: 63. Link, Google Scholar 10 : Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder carcinoma. Int Urol Nephrol1998; 30: 41. Google Scholar 11 : Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res1997; 25: 31. Google Scholar 12 : Chemotactic cytokines and tuberculosis. Biochem Soc Trans1994; 22: 310. Google Scholar 13 : Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol1996; 155: 483. Link, Google Scholar 14 : Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology2001; 57: 617. Google Scholar 15 : Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha2b for superficial bladder cancer. Clin Immunol1999; 90: 230. Google Scholar 16 : The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol2001; 165: 401. Link, Google Scholar From the Departments of Urology and Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byGrossman H (2018) Editorial: Immunotherapy for Bladder Cancer. Is the Black Box Becoming Grayer?Journal of Urology, VOL. 169, NO. 5, (1709-1709), Online publication date: 1-May-2003. Volume 168Issue 5November 2002Page: 2232-2235 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsbladder neoplasmsinterleukin-8bladderMycobacterium bovisMetricsAuthor Information ANANT KUMAR More articles by this author DEEPAK DUBEY More articles by this author PRADEEP BANSAL More articles by this author ANIL MANDHANI More articles by this author SITA NAIK More articles by this author Expand All Advertisement PDF downloadLoading ...